<code id='E05B09DECF'></code><style id='E05B09DECF'></style>
    • <acronym id='E05B09DECF'></acronym>
      <center id='E05B09DECF'><center id='E05B09DECF'><tfoot id='E05B09DECF'></tfoot></center><abbr id='E05B09DECF'><dir id='E05B09DECF'><tfoot id='E05B09DECF'></tfoot><noframes id='E05B09DECF'>

    • <optgroup id='E05B09DECF'><strike id='E05B09DECF'><sup id='E05B09DECF'></sup></strike><code id='E05B09DECF'></code></optgroup>
        1. <b id='E05B09DECF'><label id='E05B09DECF'><select id='E05B09DECF'><dt id='E05B09DECF'><span id='E05B09DECF'></span></dt></select></label></b><u id='E05B09DECF'></u>
          <i id='E05B09DECF'><strike id='E05B09DECF'><tt id='E05B09DECF'><pre id='E05B09DECF'></pre></tt></strike></i>

          
          WSS
          The New York Stock Exchange's screen displays a logo of Johnson & Johnson — pharma coverage from STAT
          AP/Richard Drew

          Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development. 

          The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry. 

          advertisement

          Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          entertainment